Cdc25 dual specificity phosphatases positively regulate the cell cycle by activating cyclin-dependent kinase/cyclin complexes. Of the three mammalian Cdc25 isoforms, Cdc25A is phosphorylated by genotoxic stress-activated Chk1 or Chk2, which triggers its SCF B-TrCP -mediated degradation. However, the roles of Cdc25B and Cdc25C in cell stress checkpoints remain inconclusive. We herein report that c-Jun NH 2 -terminal kinase (JNK) induces the degradation of Cdc25B. Nongenotoxic stress induced by anisomycin caused rapid degradation of Cdc25B as well as Cdc25A. Cdc25B degradation was dependent mainly on JNK and partially on p38 mitogen-activated protein kinase (p38). Accordingly, cotransfection with JNK1, JNK2, or p38 destabilized Cdc25B. In vitro kinase assays and site-directed mutagenesis experiments revealed that the critical JNK and p38 phosphorylation site in Cdc25B was Ser 101 . Cdc25B with Ser 101 mutated to alanine was refractory to anisomycin-induced degradation, and cells expressing such mutant Cdc25B proteins were able to override the anisomycin-induced G 2 arrest. These results highlight the importance of a novel JNK/p38-Cdc25B axis for a nongenotoxic stress-induced cell cycle checkpoint.
Introduction
Cell cycle progression in eukaryotic cells requires the successive activation and inactivation of cyclin-dependent kinase (CDK)-cyclin complexes. Activation of CDK-cyclin complexes depends on members of the Cdc25 dual specificity phosphatases. In mammalian cells, the Cdc25 family consists of Cdc25A, Cdc25B, and Cdc25C. Although Cdc25C was the first member to be identified, Cdc25A is now regarded as one of the major players in multiple phases of cell cycle progression in mammalian somatic cells (1, 2) . Besides its well-known role in G 1 -S transition, Cdc25A is also involved in the G 2 -M transition and chromosome condensation (1, 3, 4) . Moreover, Cdc25A is also a well-known target of the DNA damage checkpoint (2, 5) . On genotoxic insults, Cdc25A is rapidly phosphorylated by the checkpoint kinases Chk1 and Chk2 followed by SCF h-TrCP -mediated ubiquitinylation and degradation (2, 6) .
In contrast to Cdc25A, the roles of Cdc25B and Cdc25C remain elusive. Experiments with Cdc25B-or Cdc25C-knockout mice indicate that these genes are dispensable not only for normal cell cycle control but also for the DNA damage checkpoint (7, 8) . The only prominent phenotype is a defect in oocyte maturation in Cdc25B-depleted female mice (9) . However, several lines of evidence suggest that Cdc25B is important for controlling CDK1-cyclin B activity at the centrosome, where the kinase contributes to centrosome separation at prophase (4, 10) . Chk1 is believed to down-regulate the activity of Cdc25B until prophase (11, 12) . The phosphorylation of Cdc25B (Ser 309 of Cdc25B1 or Ser 323 in Cdc25B3) has also been implicated in the function of Cdc25B in conjunction with 14-3-3 binding (13, 14) . A mutation that abolishes the specific phosphorylation site causes Cdc25B to localize to the nucleus and enhances its ability to abrogate DNA damage-induced G 2 arrest (15, 16) . These results suggest that despite its nonessentiality in mouse models, Cdc25B does play some role in the G 2 -M transition (14) .
Stress stimuli that do not target genome DNA lead to the activation of the so-called stress-activated mitogen-activated protein kinases (MAPK), including p38 MAPK (p38) and c-Jun NH 2 -terminal kinase (JNK; ref. 17) . Recently, MAPKAP kinase 2 (MK2) has received attention for its ability to phosphorylate Cdc25B, leading to 14-3-3 binding (18) . MK2 is usually complexed with and activated by p38 (18) . Therefore, a fraction of p38 can be found to coimmunoprecipitate with MK2, which could mislead one to believe that p38 phosphorylates substrates that are normally phosphorylated exclusively by MK2. The p38-MK2 cascade is, therefore, believed to regulate cell cycle progression by controlling the stability and subcellular localization of Cdc25A and Cdc25B, respectively, when cells are exposed to genotoxic or nongenotoxic stress (14, (18) (19) (20) . JNK also phosphorylates and inactivates Cdc25C (21) . In addition, nuclear Cdc25B is exported to the cytoplasm on UV or nongenotoxic stress by an unknown mechanism (22) .
We previously reported that overexpression of 14-3-3 causes the relocation of Cdc25B from the nucleus to the cytoplasm (13, 23, 24) . To delineate the role of the cytoplasmic export of Cdc25B, we established HeLa cell lines that constitutively express Cdc25B and investigated conditions that induce nuclear export of the phosphatase. We found that nongenotoxic stress, but not genotoxic cell stress, induced loss of Cdc25B nuclear localization and that nongenotoxic stress was also an effective inducer of Cdc25B degradation. Moreover, we found that the stability of Cdc25B could be controlled by JNK and p38. These data reveal a novel pathway linking the stress response kinases to the G 2 -M cell cycle engine.
MKK6-activated p38a (both isolated from baculovirus-infected Sf21 cells) were obtained from Upstate. Oligonucleotides were synthesized by Invitrogen. The cDNAs and antibodies used in the experiments were described in Supplementary Materials and Methods.
Cell culture and plasmid transfection. HeLa cells were grown in DMEM as previously described (13) . Plasmids were transiently transfected with Lipofectamine 2000 (Invitrogen). Cell cycle synchronization was performed using the double thymidine block protocol. To obtain stable Flag-tagged Cdc25B (F-Cdc25B)-expressing HeLa cells, we used 10 Ag/mL blasticidin S (Invitrogen) for the selection of transformed cells. Established Flag-Cdc25B-expressing HeLa cells were maintained with 2 Ag/mL blasticidin S.
Preparation of crude extracts, immunoblotting, immunoprecipitation, and kinase assay. Crude extracts for the analysis of proteins followed by immunoblotting or immunoprecipitation were performed as described previously (13) . To detect endogenous Cdc25B, we subjected proteins that had been immunoprecipitated with rabbit anti-Cdc25B antibodies to SDS-PAGE, followed by immunoblotting. The Cdc25B protein was detected with mouse monoclonal anti-Cdc25B antibody. The immunoprecipitates used for the kinase assay were washed twice with buffer containing 100 mmol/L Tris-HCl (pH 8.0), 5 mmol/L EGTA, and 20 mmol/L MgCl 2 . The samples were then incubated with the same buffer that was supplemented with appropriate glutathione S-transferase (GST) fusion Cdc25B proteins, 1 mmol/L DTT, 200 Amol/L ATP, and [g-32 P]ATP (1 ACi = 37 KBq; PerkinElmer). The reaction mixtures were incubated at 30jC for 60 min and subjected to SDS-PAGE, and radioactivity was detected using the Fuji BAS system (Fujifilm).
Indirect immunofluorescence and flow cytometry. Indirect immunofluorescence of cells grown on glass coverslips was conducted as described previously (13) . Cells treated for fluorescence-activated cell sorting (FACS) were analyzed on a FACSCalibur (BD Biosciences) using ModFit software. The Ser 10 -phosphorylated histone H3 (phospho-S10-H3)-positive cells were analyzed using CellQuest software.
Results
Nuclear localization of Cdc25B is lost following treatment of cells with anisomycin but not with DNA-damaging agents. Phosphorylation of Ser 309 of Cdc25B1 followed by binding of 14-3-3 disrupts nuclear localization of Cdc25B (13) . Ser 309 can be phosphorylated by Chk1/2 and MK2 (18, 25, 26) . To determine the types of cellular stresses that induce nuclear export, we treated cells with various chemicals and analyzed the subcellular localization of Cdc25B. Given that an antibody that displayed high specificity toward endogenous Cdc25B was not available commercially or in house, we first established a HeLa cell-based cell line that constitutively expressed F-Cdc25B. No gross abnormality of cell growth or morphology was discerned for F-Cdc25B-expressing cells, which are hereafter called HeLa-W40 cells.
We treated HeLa-W40 cells with hydroxyurea, aphidicolin, etoposide, or camptothecin, which activate either Chk1 or Chk2. DNA damage induced by the chemicals was confirmed by assaying for phosphorylated histone H2AX (g-H2AX; ref. 27). Cdc25B localized to the nucleus in cells with or without DNA damage or replication arrest (Fig. 1A ). We next investigated the possible involvement of the p38/MK2 pathways in this process. To activate the p38/MK2 pathway, we treated the cells with anisomycin, which activates p38 and JNK (28, 29) . Treatment with anisomycin disrupted the nuclear localization of Cdc25B and promoted the redistribution of Cdc25B to the cytoplasm (Fig. 1B) . These results suggest that Cdc25B nuclear localization can be disrupted by stress pathways other than those initiated by DNA damage.
To assess the possibility that the p38 pathway regulates Cdc25B, we added the p38 inhibitor SB202190 to HeLa-W40 cells. Of interest is that SB202190 exerted only a small effect on the anisomycininduced diffusion of Cdc25B (Fig. 1C) . In contrast, the JNK inhibitor SP600125 induced strong nuclear staining of Cdc25B under conditions of anisomycin stress. Furthermore, stronger nuclear signals for Cdc25B were generated by simultaneous treatment with both SB202190 and SP600125 than by treatment with SP600125 alone. Inhibition of MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK1) with U0126, thereby inhibiting the activation of ERK1/2, did not prevent cytoplasmic diffusion of Cdc25B (data not shown). Collectively, these data indicate that anisomycin-mediated stress can disrupt nuclear localization of Cdc25B in a JNK-dependent manner.
Cdc25B is degraded in cells treated with anisomycin or sodium chloride but not with DNA-damaging agents. The signals for F-Cdc25B faded in cells after long-term exposure to anisomycin but not after treatment with DNA-damaging agents (data not shown). These observations led us to analyze the level of F-Cdc25B protein in HeLa-W40 cells treated with anisomycin and another Figure 1 . Nuclear localization of Cdc25B is maintained after DNA damage but is disturbed by anisomycin treatment. A, HeLa-W40 cells were treated with the indicated chemicals and Flag-Cdc25B and g-H2AX were detected by indirect immunofluorescence. The nuclei were identified using 4 ¶,6-diamidino-2-phenylindole. The conditions for chemical treatment were described in Supplementary Materials and Methods. B, HeLa-W40 cells were treated with 50 ng/mL anisomycin for 15 min and processed for indirect immunofluorescence. C, HeLa-W40 cells were pretreated with the indicated MAPK inhibitors for 1 h followed by anisomycin challenge. The cells were fixed, and Flag-Cdc25B and nuclei were analyzed. The concentration for inhibitors was as follows: SB202190, 20 Amol/L; SP600125, 20 Amol/L.
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www.aacrjournals.org nongenotoxic reagent, sodium chloride (NaCl). We also examined the levels of Cdc25A and Cdc25C to determine whether different cellular stresses affect members of this phosphatase family. Genotoxic stress caused by exposure to hydroxyurea, aphidicolin, etoposide, or camptothecin effectively induced Cdc25A degradation ( Fig. 2A) . In contrast, expression of Cdc25B or Cdc25C was unaffected under the same conditions. Although neither anisomycin nor NaCl activated Chk1 or Chk2, both Cdc25B and Cdc25A were degraded (Fig. 2A) . Cdc25A and Cdc25B decreased in a timedependent fashion after exposure to anisomycin (Fig. 2B) . The endogenous Cdc25B protein in parental HeLa cells was also degraded by anisomycin treatment but not by DNA-damaging agents ( Supplementary Fig. S1 ). The abundance of Cdc25C was not affected by any of the stimuli examined here. UV irradiation, which is known to activate not only Chk1/2 but also p38/JNK, abrogated nuclear localization of Cdc25B as reported (22) and induced Cdc25B degradation ( Supplementary Fig. S2A and B) .
Although anisomycin inhibits protein synthesis (29) , the more rapid decline of Cdc25B in anisomycin-treated cells compared with cycloheximide-treated cells suggested that degradation of Cdc25B was specifically caused by anisomycin-induced stress and not by a general inhibition of protein synthesis (Fig. 2C) Figure 2D shows that Cdc25B DAA was unstable after anisomycin treatment. This indicates that the Cdc25B degradation was specific to anisomycin treatment. Collectively, these data indicate that anisomycin-induced stress, but not DNA damage-induced stress, triggers a loss of nuclear localization and stability of Cdc25B.
Inhibition of JNK attenuates the degradation of Cdc25B by anisomycin. To determine the role of p38 or JNK on the stability of Cdc25A and Cdc25B, we treated HeLa cells with inhibitors of p38 or JNK and analyzed the cellular proteins. The activation of p38a/h was monitored as the slower migrating form of MK2, corresponding to phosphorylated MK2 (Fig. 3A) ; JNK activation was monitored using antibodies recognizing phospho-JNK1 or phospho-c-Jun. We found that the JNK inhibitor SP600125 protected Cdc25B from anisomycin-induced degradation (Fig. 3A, lanes 5-8) . A relatively small but definite contribution of the p38 pathway to the degradation of Cdc25B was revealed by these experiments (Fig. 3A,  lanes 3-8) . The MEK1 inhibitor U0126 again had no effect on the stability of either Cdc25A or Cdc25B (data not shown). Time course experiments further validated the critical role of JNK in regulating the degradation of Cdc25B (Fig. 3B) . The stability of Cdc25C was essentially unaffected by these inhibitors (Fig. 3A) . Exactly the same results were obtained with HeLa-W40 cells that expressed F-Cdc25B (Supplementary Fig. S3A ). JNK inhibitor also attenuated the NaCl-induced F-Cdc25B degradation ( Supplementary  Fig. S3B ). Results shown in Fig. 3C indicate the correlation between the degradation of Cdc25A/Cdc25B and activation of p38/JNK. Anisomycin-, NaCl-, or UV-induced degradation of Cdc25B was inhibited by the proteasome inhibitor MG132, suggesting that the anisomycin-induced degradation of Cdc25B is mediated by the ubiquitin-proteasome pathway ( Supplementary Fig. S3C, 1, 2, and 3) . Degradation of Cdc25A and Cdc25B after treatment with DNA-damaging or non-DNA-damaging agents. A, HeLa-W40 cells were treated with genotoxic chemicals as described in Supplementary Materials and Methods. The cells were incubated with anisomycin or 300 mmol/L NaCl for 30 min or 1 h, respectively. Cell extracts were prepared, and indicated proteins were detected by immunoblotting. h-Actin analysis serves as a loading control. B, parental HeLa cells were treated with anisomycin, and cell extracts were prepared at the indicated time to detect endogenous Cdc25A, Cdc25B, and Cdc25C. C, HeLa-W40 cells were treated with anisomycin or 50 Ag/mL cycloheximide. Crude extracts were prepared at the indicated time, and the expression of Flag-Cdc25B was analyzed. D, HeLa cells constitutively expressing the Cdc25B DAA mutant were treated with anisomycin or cycloheximide and the expression of Flag-Cdc25B proteins was determined by immunoblotting.
Results of indirect immunofluorescence also supported that the instability of Cdc25B in anisomycin-treated cells was due to its proteasome-dependent degradation (Supplementary Fig. S3D ).
The coexpression of either JNK1 or JNK2 with MKK7 triggered Cdc25B degradation (Fig. 4A ). In addition, p38a was able to induce Cdc25B degradation. Furthermore, the expression of kinase-dead JNK1 and JNK2 stabilized Cdc25B (Fig. 4B) , indicating dominantnegative effects. We further examined the contribution of MK2 to Cdc25B degradation. In this experiment, we used the D316N mutant of p38a, which is unable to activate MK2 (31) . As shown in Fig. 4C , expression of p38a D316N induced the degradation of Cdc25B. Taken together, these results suggest that JNK and p38 are integrally involved in Cdc25B degradation.
JNK phosphorylates Cdc25B. We found that bacterially expressed Cdc25B was phosphorylated by kinase-active JNK1 but not by its kinase-dead form, indication that JNK1 can directly phosphorylate Cdc25B (Supplementary Fig. S4A ). Likewise, recombinant JNK1 could also phosphorylate Cdc25B (Supplementary Fig. S4B ). To identify the phosphorylation site(s) on Cdc25B, GST fusion constructs of different fragments of Cdc25B were produced in Escherichia coli and used as substrates for kinase assays. As shown in Fig. 5A , JNK phosphorylation sites were present in the NH 2 -terminal 175 amino acids. The same fragment was also phosphorylated by recombinant p38a (Supplementary Fig. S4C ). Furthermore, JNK and Cdc25B were able to form complex, which supports the idea of Cdc25B being a JNK substrate [Supplementary Fig. S5A ; the loss of the complex formation in wild-type (WT) JNK with MKK7 suggests that JNK may dislodge after phosphorylation event]. The importance of the NH 2 -terminal region was also supported by the JNK-induced degradation of the construct containing green fluorescent protein fused to the NH 2 -terminal 175 amino acid fragment of Cdc25B (Supplementary Fig. S5B ).
Cdc25B/S101 is a candidate JNK phosphorylation site. To identify JNK phosphorylation site(s), we first mutated all six candidate serine residues to alanine in six potential JNK substrate SP sequences (and no TP) in N175-Cdc25B. The 6SA mutant was refractory to JNK-or p38a-induced degradation ( Supplementary  Fig. S6A ). The coexpression of the individual SA mutant Cdc25B with JNK indicated the importance of S101, followed by S103 (Fig. 5B) . The importance of S101 and S103 was further supported by the slower degradation rate of the Cdc25B protein with a double mutation (S101/103A) compared with the mutants with a single mutation (Fig. 5C, lanes 4, 6, and 8) . Essentially the same results were obtained when p38a was used as a kinase for the Cdc25B mutants ( Supplementary Fig. S6B ). Taken together, these data indicate that phosphorylation of Cdc25B at S101 and S103 by JNK and p38 is important for degradation.
HeLa cells expressing the Cdc25B S101A mutant ignore anisomycin-induced G 2 arrest. We next examined the effects of anisomycin on cell cycle progression, in particular during G 2 -M phase, when Cdc25B peaks during the cell cycle. HeLa cells were synchronized at G 1 -S and released into S phase. At 6 hours after release, the cells were treated with anisomycin followed by monitoring of M-phase entry by detection of phospho-S10-H3. Cdc25B and phospho-S10-H3 increased progressively in DMSO-treated cells (Fig. 6A) , but no phospho-S10-H3 was detected in anisomycintreated cells, indicating that anisomycin treatment inhibited mitotic entry. In such cells, Cdc25B disappeared completely by 30 minutes after addition of anisomycin (Fig. 6A, lanes 7 and 8) . FACS analysis confirmed the induction of a G 2 delay by anisomycin treatment in synchronously or asynchronously growing HeLa cells (Supplementary Fig. S7A ).
To delineate the significance of Cdc25B S101 phosphorylation in anisomycin-induced G 2 arrest, we added anisomycin to asynchronously growing HeLa cells that constitutively express the nonphosphorylatable Cdc25B S101A mutant (HeLa-101-1) . The results shown in Fig. 6B indicate that the half-life of the S101A mutant Cdc25B was twice as long as that of the WT after anisomycin treatment (f35 minutes in S101A and f15 minutes in WT), indicating that phosphorylation of S101 is essential for proper degradation. Treatment of HeLa-101-1 with either NaCl or UV also supported the idea that S101 is important for stress-induced Cdc25B degradation (Supplementary Fig. S8A ).
We next investigated whether the S101A mutant would exhibit abrogation of anisomycin-induced G 2 arrest. We used cell lines expressing WT Cdc25B (W40) or S101A (101-1). The amount of Cdc25B protein in W40 cells and that of 101-1 is shown in Supplementary Fig. S7B . Asynchronously growing HeLa cells, W40 cells, and 101-1 cells were treated with 100 ng/mL anisomycin, and the number of cells entering M phase during a 3-hour treatment with anisomycin was determined by detecting phospho-S10-H3. As shown in Fig. 6C , HeLa-101-1 cells exhibited resistance to anisomycin-induced G 2 retardation. Thus, cells expressing S101A-mutated Cdc25B seem to be more resistant to anisomycin-induced degradation and to recover more rapidly than WT Cdc25B-expressing cells.
Collectively, HeLa cells expressing Cdc25B with a nonphosphorylatable mutation at the possible JNK target S101 residue were more refractory to anisomycin-induced cell cycle retardation.
Discussion
We report here for the first time that Cdc25B is targeted for degradation in cells that are challenged with anisomycin or NaCl and that the degradation of Cdc25B is mediated mainly by JNK. We uncovered this phenomenon by using HeLa cells that constitutively expressed recombinant Cdc25B. In our hands, commercially available antibodies did not properly recognize endogenous Cdc25B in crude extracts by immunoblotting. Immunoprecipitation followed by immunoblotting was necessary to detect endogenous Cdc25B.
Our experiments highlight the critical role of JNK in controlling Cdc25B stability. A level of DNA damage that is sufficient for activating Chk1/2 and Cdc25A degradation did not exert any effects on the stability of Cdc25B. Export of Cdc25B from the nucleus to the cytoplasm is thought to be a mechanism of checkpoint response (18) . However, Cdc25B did not follow this expected pattern after DNA damage (Fig. 1A) . We therefore suspect that Cdc25B is not a primary target of the DNA damage checkpoint, although we cannot exclude the possibility that its phosphatase activity is directly repressed by a Chk1-dependent mechanism (32) .
We showed that M-phase entry is delayed in HeLa cells treated with anisomycin (Fig. 6 ). The G 2 retardation observed in this situation is caused in part by the degradation of Cdc25A and Cdc25B. Depletion of either Cdc25A or Cdc25B is insufficient for G 2 -phase arrest, but the depletion of both Cdc25A and Cdc25B is necessary for a more robust G 2 arrest (4). Therefore, anisomycin-induced G 2 Figure 5 . Phosphorylation of Cdc25B by JNK at possible phosphorylation sites. A, left, GST-Cdc25B fragments were incubated with a recombinant JNK1 in the presence of [g-32 P]ATP followed by autoradiography; right, substrate GST-Cdc25B fragment as detected by anti-GST antibody. B, WT Cdc25B or mutants that contained SA mutations at candidate JNK phosphorylation sites were cotransfected into HeLa cells with or without MKK7 and JNK1, and expression of Cdc25B was determined by immunoblotting. C, the WT or SA mutant at S101, S103, or S101/103 was cotransfected into HeLa cells with or without MKK7 and JNK1, and the expression of Cdc25B was determined. retardation can be explained at least in part by the simultaneous degradation of Cdc25A and Cdc25B (Fig. 2) . Our results strongly suggest the presence of a nongenotoxic stress-dependent cell cycle checkpoint wherein Cdc25 phosphatases are degraded to downregulate CDK activity. This checkpoint is mediated by stressactivated MAPKs, including p38 and JNK, as depicted in Fig. 6D . The proteasome inhibitor MG132 attenuated anisomycin-induced Cdc25B degradation, which strongly suggests that Cdc25B is degraded by the ubiquitin-proteasome pathway. Cdc25B is degraded in the steady state by the SCF h-TrCP -mediated ubiquitinylation mechanism. It is unlikely that phosphorylation of S101 stimulated binding of SCF h-TrCP to the constitutive binding site, which is located more than 100 amino acids downstream of S101. It is necessary to identify the responsible ubiquitinylation system to understand JNK-mediated Cdc25B degradation more precisely. Several reports have indicated a correlation between the malignancy of tumors and the overexpression of Cdc25A and Cdc25B (33, 34) . Cdc25A and Cdc25B are oncogenic (35) , and Cdc25A is a main target of the DNA damage checkpoint (1, 2, 34) . Assuming that Cdc25B is a target of a nongenotoxic stress checkpoint, overexpression of Cdc25B may allow cells to become less sensitive to intrinsically harmful cell stresses that do not directly compromise genome integrity. Ignoring the detrimental stress signal, such as NaCl-induced distortion of the cytoskeleton by hyperosmolarity or anisomycin-induced inhibition of protein synthesis, may disrupt the proper regulation of chromosome segregation and cytokinesis during mitosis, which are well-known causative events of genome instability (36) .
In conclusion, we have shown that Cdc25B is targeted for JNKmediated degradation by cellular stress. The stress-induced checkpoint is initiated by the activation of JNK and p38, which phosphorylates Ser 101 of Cdc25B. This results in the rapid degradation of Cdc25B and cell cycle arrest.
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No potential conflicts of interest were disclosed. Figure 6 . The Cdc25B mutant is refractory to anisomycin-induced G 2 arrest. A, HeLa cells synchronized at G 1 -S were released into the cell cycle for 6 h, followed by the addition of anisomycin. At the indicated times, the expression of proteins was determined. B, HeLa-W40 or HeLa-101-1 cells were treated with anisomycin, and the expression of the proteins was determined at the indicated time points after treatment. Bottom, quantitative results. Typical results of three independent experiments are shown. C, asynchronously growing HeLa, HeLa-W40, or HeLa-101-1 cells were treated with 100 ng/mL anisomycin and 100 ng/mL nocodazole for 3 h. Cells were collected, and the cells in M phase were determined by detecting phospho-histone H3-Ser 10 by FACS. Columns, mean of three independent experiments; bars, SD. The percentage of mitotic cells in asynchronous cells was as follows: HeLa, 2.76 F 0.27; W40, 3.57 F 0.13; 101-1, 3.61 F 0.14. D, a model of the induction of Cdc25A and Cdc25B degradation after nongenotoxic stress followed by G 2 arrest.
